Next Article in Journal
Echinacea—A Source of Potent Antivirals for Respiratory Virus Infections
Next Article in Special Issue
The Endocannabinoid System as Pharmacological Target Derived from Its CNS Role in Energy Homeostasis and Reward. Applications in Eating Disorders and Addiction
Previous Article in Journal / Special Issue
Psychostimulant Drugs and Neuroplasticity

Methylenedioxymethamphetamine (MDMA, 'Ecstasy'): Neurodegeneration versus Neuromodulation

Department of Pharmacology, School of Pharmacy, University of Navarra, Irunlarrea 1, 31008 Pamplona, Spain
Author to whom correspondence should be addressed.
Pharmaceuticals 2011, 4(7), 992-1018;
Received: 22 April 2011 / Revised: 15 June 2011 / Accepted: 4 July 2011 / Published: 5 July 2011
(This article belongs to the Special Issue Drug Abuse Targets)
The amphetamine analogue 3,4-methylenedioxymethamphetamine (MDMA, ‘ecstasy’) is widely abused as a recreational drug due to its unique psychological effects. Of interest, MDMA causes long-lasting deficits in neurochemical and histological markers of the serotonergic neurons in the brain of different animal species. Such deficits include the decline in the activity of tryptophan hydroxylase in parallel with the loss of 5-HT and its main metabolite 5-hydoxyindoleacetic acid (5-HIAA) along with a lower binding of specific ligands to the 5-HT transporters (SERT). Of concern, reduced 5-HIAA levels in the CSF and SERT density have also been reported in human ecstasy users, what has been interpreted to reflect the loss of serotonergic fibers and terminals. The neurotoxic potential of MDMA has been questioned in recent years based on studies that failed to show the loss of the SERT protein by western blot or the lack of reactive astrogliosis after MDMA exposure. In addition, MDMA produces a long-lasting down-regulation of SERT gene expression; which, on the whole, has been used to invoke neuromodulatory mechanisms as an explanation to MDMA-induced 5-HT deficits. While decreased protein levels do not necessarily reflect neurodegeneration, the opposite is also true, that is, neuroregulatory mechanisms do not preclude the existence of 5-HT terminal degeneration. View Full-Text
Keywords: 3,4-methylenedioxymethamphetamine (MDMA, ‘ecstasy’); 5-hydroxy- tryptamine (5-HT, serotonin); neurotoxicity 3,4-methylenedioxymethamphetamine (MDMA, ‘ecstasy’); 5-hydroxy- tryptamine (5-HT, serotonin); neurotoxicity
Show Figures

MDPI and ACS Style

Puerta, E.; Aguirre, N. Methylenedioxymethamphetamine (MDMA, 'Ecstasy'): Neurodegeneration versus Neuromodulation. Pharmaceuticals 2011, 4, 992-1018.

AMA Style

Puerta E, Aguirre N. Methylenedioxymethamphetamine (MDMA, 'Ecstasy'): Neurodegeneration versus Neuromodulation. Pharmaceuticals. 2011; 4(7):992-1018.

Chicago/Turabian Style

Puerta, Elena, and Norberto Aguirre. 2011. "Methylenedioxymethamphetamine (MDMA, 'Ecstasy'): Neurodegeneration versus Neuromodulation" Pharmaceuticals 4, no. 7: 992-1018.

Find Other Styles

Article Access Map by Country/Region

Only visits after 24 November 2015 are recorded.
Back to TopTop